Loading...
Market
What will be the revenue generated by Miplyffa for Zevra Therapeutics in the fiscal year 2024?
3
Resolution / Starting Odds
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Zevra Therapeutics' financial statements and earnings reports
Story
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C
Sep 20, 2024, 03:42 PM
The U.S. Food and Drug Administration (FDA) has approved the first oral medication to treat Niemann-Pick disease, type C (NPC). The drug, developed by Zevra Therapeutics and named Miplyffa (arimoclomol), is approved in combination with miglustat for patients aged 2 and older. This marks the first treatment to receive approval for this rare and fatal genetic disorder. The approval was announced on Friday. Zevra Therapeutics is listed under the ticker symbol ZVRA.
View original story
Similar markets
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%